AtriCure Enrolls First Patient in BoxX-NoAF Study
AtriCure (Nasdaq:ATRC) announced the enrollment of the first patient in its BoxX-NoAF clinical trial, evaluating its cardiac therapy technologies.
The BoxX-NoAF trial aims to define clinical practice and treatment guidelines for reducing post-operative AFib (POAF) and longer-term clinical AFib in elevated-risk cardiac surgery patients.
- The study investigates concomitant surgical ablation with left atrial appendage (LAA) management.
- Investigators seek to determine if this approach reduces the occurrence of new-onset AFib POAF compared to no treatment.
Anthony Rongione treated the first patient at Orlando Health Heart and Vascular Institute.
No direct quote available in the text.
Author's summary: AtriCure starts BoxX-NoAF trial to reduce AFib in cardiac surgery patients.
More News
- Babar Azam, Mohammad Rizwan in focus: PCB clears Big Bash NOCs for Pakistan players, but with a catch
- Flight Booking, Cheap Flights, Air Tickets at Lowest Fare
- Women’s Big Bash League 2025-26 results
- Sydney Sixers Vs Adelaide Strikers, WBBL 2025: SYS-W Beat AS-W By One Run Thanks To Ellyse Perry Century
- Vilnius Airport grounds flights after suspected Belarusian balloons detected
- Delegates delayed at Brynglas Tunnels is Drakeford's fault
- IndiGo Flights Cancellation Live Updates
- GRIDLOCK Definition & Meaning
- Hundreds stranded after IndiGo canceled 1,000 flights in India air travel chaos
- Gridlocked Halloween, 2025, @kaltgatzke flashbang film. I ...